QED Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:N/A
Lead Investor(s):BridgeBio Pharma

Estimated Revenue & Financials

  • QED Therapeutics's estimated annual revenue is currently $9.9M per year.(?)
  • QED Therapeutics received $65.0M in venture funding in January 2018.
  • QED Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • QED Therapeutics has 64 Employees.(?)
  • QED Therapeutics grew their employee count by 100% last year.
  • QED Therapeutics currently has 4 job openings.

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.